Collectively, BRCA1-IRIS overexpression appears to promote formation of aggressive, invasive and/or metastatic breast cancers and implies that inhibiting BRCA1-IRIS expression and/or activity could be pursued as a novel therapeutic option to treat breast cancer patients, especially those with HER2+ and/or TN/BL diseases. This evidence concerns the gene BRCA1 and breast cancer.